Ftse Mib
34.657,44
0,93%
DAX
18.782,16
0,55%
S&P 500
5.217,49
0,07%
NASDAQ
16.340,86
-0,03%
Bitcoin
61.116,19
-3,06%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Janux Therapeutics Inc (JANX) Janux Therapeutics Inc (JANX) Notizie

JANX

Janux Therapeutics (JANX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:JANX
DataOraFonteTitoloSimboloCompagnia
08/05/202415:13Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:JANXJanux Therapeutics Inc
07/05/202422:01Business WireJanux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
08/03/202422:47Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:JANXJanux Therapeutics Inc
08/03/202422:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:JANXJanux Therapeutics Inc
08/03/202422:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
08/03/202422:01Business WireJanux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
29/02/202423:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
29/02/202407:22Business WireJanux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:JANXJanux Therapeutics Inc
29/02/202403:55Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:JANXJanux Therapeutics Inc
27/02/202423:00Business WireJanux Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:JANXJanux Therapeutics Inc
26/02/202422:05Business WireJanux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid TumorsNASDAQ:JANXJanux Therapeutics Inc
20/02/202414:00Business WireJanux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008NASDAQ:JANXJanux Therapeutics Inc
09/02/202422:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
08/01/202415:00Business WireJanux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific OfficerNASDAQ:JANXJanux Therapeutics Inc
03/01/202422:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202422:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
07/11/202322:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:JANXJanux Therapeutics Inc
07/11/202322:01Business WireJanux Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
08/09/202300:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
08/08/202322:01Business WireJanux Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
17/07/202314:45Business WireJanux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:JANXJanux Therapeutics Inc
17/07/202314:00Business WireJanux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline ProgramsNASDAQ:JANXJanux Therapeutics Inc
23/06/202322:37Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:JANXJanux Therapeutics Inc
16/06/202323:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:JANXJanux Therapeutics Inc
05/06/202322:35Business WireJanux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical DevelopmentNASDAQ:JANXJanux Therapeutics Inc
30/05/202322:46Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:JANXJanux Therapeutics Inc
09/05/202323:07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:JANXJanux Therapeutics Inc
09/05/202322:17Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:JANXJanux Therapeutics Inc
09/05/202322:01Business WireJanux Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
28/04/202323:09Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:JANXJanux Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:JANX

La tua Cronologia

BIT
ENEL
Enel
BIT
UCG
Unicredit
BIT
BFF
BFF Bank
BIT
ISP
Intesa Sanpaolo
BIT
LDO
Leonardo
BIT
IVG
Iveco Group NV
BIT
RACE
Ferrari NV
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
NEXI
Nexi S.p.A
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
MB
Mediobanca Banca di Cred...
BIT
PRY
Prysmian
BIT
STMMI
ST Microelectronics
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network